Literature DB >> 6133828

Opioid peptide effects on insulin release and c-AMP in islets of Langerhans.

I C Green, K Ray, D Perrin.   

Abstract

The time course and specificity of the effect of opioid peptides on c-AMP production in the islets of Langerhans was examined. An enkephalin analogue, d-Ala2Me Phe4 Met(O)-ol enkephalin (DAMME, Sandoz) produced a significant stimulation of basal c-AMP levels, with a peak of stimulation at 5 minutes and a decline thereafter. These changes in intracellular c-AMP levels were of the same order of magnitude as those induced by other secretagogues, but did not coincide in time with the more rapid peak of enkephalin-induced insulin release. The rise in islet c-AMP and insulin secretion induced by DAMME and alpha-endorphin but not leu enkephalin was antagonised by naloxone. The effects of high and low concentrations of a variety of opioid peptides and naloxone on insulin release and islet c-AMP levels were determined, alpha-endorphin, dynorphin, leu enkephalin and met enkephalin all stimulated insulin secretion significantly, though not to the same extent. Higher concentrations of alpha-endorphin, dynorphin and met enkephalin inhibited insulin release relative to effects at low opiate concentrations. However, higher concentrations of leu enkephalin stimulated insulin release further. We conclude from these results that the mode of action of opioid peptides in stimulating insulin release is not via increased islet c-AMP exclusively. Furthermore, the results obtained with different classes of opioid suggest the presence of distinctive types of opiate receptor in islets of Langerhans.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6133828     DOI: 10.1055/s-2007-1018648

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  9 in total

Review 1.  Opioid peptides and glucose metabolism.

Authors:  A Lala; P Bouloux; G Tamburrano; E Gale
Journal:  J Endocrinol Invest       Date:  1987-02       Impact factor: 4.256

2.  Comparison of the effects of [leucine]enkephalin and angiotensin on hepatic carbohydrate and cyclic nucleotide metabolism.

Authors:  S K Hothi; R P Leach; M A Titheradge
Journal:  Biochem J       Date:  1988-02-01       Impact factor: 3.857

Review 3.  Neuropeptidergic versus cholinergic and adrenergic regulation of islet hormone secretion.

Authors:  B Ahrén; G J Taborsky; D Porte
Journal:  Diabetologia       Date:  1986-12       Impact factor: 10.122

4.  The stimulation of glycogenolysis in isolated hepatocytes by opioid peptides.

Authors:  R P Leach; M A Titheradge
Journal:  Biochem J       Date:  1986-09-01       Impact factor: 3.857

5.  Opioid receptors on guinea-pig intestinal crypt epithelial cells.

Authors:  M E Lang; J S Davison; S L Bates; J B Meddings
Journal:  J Physiol       Date:  1996-11-15       Impact factor: 5.182

6.  Interleukin-1 beta effects on cyclic GMP and cyclic AMP in cultured rat islets of Langerhans-arginine-dependence and relationship to insulin secretion.

Authors:  I C Green; C A Delaney; J M Cunningham; V Karmiris; C Southern
Journal:  Diabetologia       Date:  1993-01       Impact factor: 10.122

7.  The occurrence and receptor specificity of endogenous opioid peptides within the pancreas and liver of the rat. Comparison with brain.

Authors:  X Z Khawaja; I C Green; J R Thorpe; M A Titheradge
Journal:  Biochem J       Date:  1990-04-01       Impact factor: 3.857

Review 8.  Neural pathways that control the glucose counterregulatory response.

Authors:  Anthony J M Verberne; Azadeh Sabetghadam; Willian S Korim
Journal:  Front Neurosci       Date:  2014-02-26       Impact factor: 4.677

9.  Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers.

Authors:  Frederico G S Toledo; William F Martin; Linda Morrow; Carine Beysen; Daiva Bajorunas; Ying Jiang; Bernard L Silverman; David McDonnell; Mark N Namchuk; John W Newcomer; Christine Graham
Journal:  Neuropsychopharmacology       Date:  2021-12-09       Impact factor: 7.853

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.